{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"IOV-COM-202","nct_id":"NCT03645928","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=iov-com-202-nct03645928. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Lifileucel (LN-144) regimen in combination with pembrolizumab in patients with Stage IIIC to IV unresectable or metastatic melanoma with ≤ 3 prior lines of systemic therapy, excluding immune checkpoint inhibitors (ICI).","label":"Cohort 1A","type":"EXPERIMENTAL"},{"description":"LN-145-S1 regimen in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is proto-oncogene B-Raf (BRAF) V600 mutation positive, patients must have received a BRAF inhibitor with or without a mitogen-activated extracellular signal-related kinase (MEK) inhibitor.","label":"Cohort 1B","type":"EXPERIMENTAL"},{"description":"Lifileucel (LN-144 Generation 3 \\[Gen 3\\]) regimen in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is BRAF V600 mutation positive, patients must have received BRAF inhibitor with or without a MEK inhibitor.","label":"Cohort 1C","type":"EXPERIMENTAL"},{"description":"Lifileucel (LN-145) regimen in combination with pembrolizumab in patients with advanced, recurrent, or metastatic HNSCC, with ≤ 3 prior lines of systemic therapy, excluding ICIs.","label":"Cohort 2A","type":"EXPERIMENTAL"},{"description":"Lifileucel (LN-145) regimen in combination with pembrolizumab in patients with locally advanced or metastatic (Stage III or Stage IV) non-small-cell lung cancer (NSCLC) with ≤ 3 prior lines of systemic therapy, excluding ICIs, or ≤ 4 lines if 2 or more of the lines are tyrosine kinase inhibitor (TKI) therapy for those with tumors that harbored actionable mutations (eg, EGFR, ALK, ROS).","label":"Cohort 3A","type":"EXPERIMENTAL"},{"description":"Lifileucel (LN-145) regimen ent in patients with Stage III or Stage IV NSCLC, who have previously received 1-3 lines of prior systemic therapy. Patients with known oncogene drivers (eg, EGFR, ALK, ROS) who have mutations that are sensitive to targeted therapies are not required to have received prior systemic therapy with ICIs.","label":"Cohort 3B","type":"EXPERIMENTAL"},{"description":"Lifileucel (LN-145) regimen in combination with ipilimumab and nivolumab in patients with Stage III or Stage IV NSCLC who have previously received 1 line of ICI monotherapy. No other systemic therapy for metastatic disease is allowed. Prior chemoradiation and/or chemotherapy in the adjuvant and/or neo-adjuvant settings are allowed.","label":"Cohort 3C","type":"EXPERIMENTAL"},{"description":"Lifileucel regimen in combination with pembrolizumab with or without pemetrexed, given after tumor resection then 4 cycles of frontline platinum doublet chemotherapy plus pembrolizumab, in patients with Stage IV NSCLC without EGFR, ALK, or ROS1 driver mutations, who have had no prior therapy for advanced disease.","label":"Cohort 3D","type":"EXPERIMENTAL"},{"description":"Lifileucel regimen in combination with pembrolizumab with or without pemetrexed, given after 4 cycles of frontline platinum doublet chemotherapy plus pembrolizumab with tumor resection between any 2 cycles, in patients with Stage IV NSCLC without EGFR, ALK, or ROS1 driver mutations.","label":"Cohort 3E","type":"EXPERIMENTAL"},{"description":"Lifileucel (LN-144) regimen in combination with nivolumab-relatlimab in patients with Stage IIIC to IV unresectable or metastatic (advanced) melanoma who have had no prior therapy for advanced disease.","label":"Cohort 1D","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-02-20","type":"ACTUAL"},"conditions":["Metastatic Melanoma","Squamous Cell Carcinoma of the Head and Neck","Non-small Cell Lung Cancer"],"enrollment":{"count":225,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Lifileucel","otherNames":["LN-144, TIL, autologous tumor-infiltrating lymphocytes"],"type":"BIOLOGICAL"},{"name":"LN-145","otherNames":["TIL, autologous tumor infiltrating lymphocytes"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"},{"name":"LN-145-S1","otherNames":["TIL, autologous tumor-infiltrating lymphocytes, PD-1-selected TIL"],"type":"BIOLOGICAL"},{"name":"Ipilimumab","otherNames":["Yervoy"],"type":"DRUG"},{"name":"Nivolumab","otherNames":["Opdivo"],"type":"DRUG"},{"name":"Nivolumab-relatlimab","otherNames":["Opdualag"],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Nab paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-15","lead_sponsor":"Iovance Biotherapeutics, Inc.","official_title":"A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-02-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate","timeFrame":"Up to 60 months"},{"measure":"Safety Profile Measured by Grade ≥3 TEAEs","timeFrame":"Up to 60 months"},{"measure":"Percentage of patients for whom lifileucel is successfully manufactured and meets release specification","timeFrame":"Up to 60 months"}],"references":[{"citation":"Hensel J, Metts J, Gupta A, Ladle BH, Pilon-Thomas S, Mullinax J. Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy. Cancer J. 2022 Jul-Aug 01;28(4):322-327. doi: 10.1097/PPO.0000000000000603.","pmid":"35880942","type":"DERIVED"}],"start_date":{"date":"2019-05-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","url":"https://clinicaltrials.gov/study/NCT03645928"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/iov-com-202-nct03645928"}